Does the media refer more to TARS or DRUG?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for Bright Minds Biosciences. Tarsus Pharmaceuticals' average media sentiment score of 0.14 beat Bright Minds Biosciences' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TRVI or DRUG?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is TRVI or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Bright Minds Biosciences N/A -20.58% -20.25%

Which has higher valuation and earnings, MBX or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is MBX or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Bright Minds Biosciences N/A -20.58% -20.25%

Does the media prefer MBX or DRUG?

In the previous week, MBX Biosciences had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Bright Minds Biosciences. MBX Biosciences' average media sentiment score of 0.00 equaled Bright Minds Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DRUG or NRIX?

In the previous week, Nurix Therapeutics had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Nurix Therapeutics and 1 mentions for Bright Minds Biosciences. Nurix Therapeutics' average media sentiment score of 0.41 beat Bright Minds Biosciences' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, DRUG or KOD?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is DRUG or KOD more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Kodiak Sciences N/A -253.85% -81.48%

Does the media prefer DRUG or KOD?

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 0.00 equaled Kodiak Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bright Minds Biosciences (DRUG) Competitors

$67.60 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$68.50 +0.90 (+1.33%)

As of 07/2/2026 07:58 PM Eastern

Compare

DRUG vs. TARS, TRVI, MBX, NRIX, and KOD

Should you buy Bright Minds Biosciences stock or one of its competitors? MarketBeat compares Bright Minds Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bright Minds Biosciences include Tarsus Pharmaceuticals (TARS), Trevi Therapeutics (TRVI), MBX Biosciences (MBX), Nurix Therapeutics (NRIX), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Bright Minds Biosciences compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bright Minds Biosciences has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.24	-$66.42M	-$1.14	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, suggesting a potential upside of 38.55%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 112.77%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Bright Minds Biosciences has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for Bright Minds Biosciences. Tarsus Pharmaceuticals' average media sentiment score of 0.14 beat Bright Minds Biosciences' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, suggesting that its share price is 634% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Bright Minds Biosciences on 9 of the 16 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Bright Minds Biosciences' return on equity of -20.58% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, Bright Minds Biosciences had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 1 mentions for Bright Minds Biosciences and 0 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.00 equaled Bright Minds Biosciences'average media sentiment score.

Company	Overall Sentiment
Trevi Therapeutics	Neutral
Bright Minds Biosciences	Neutral

Trevi Therapeutics currently has a consensus target price of $22.67, suggesting a potential upside of 26.42%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 112.77%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Trevi Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Bright Minds Biosciences has a beta of -5.34, suggesting that its share price is 634% less volatile than the broader market.

Summary

Bright Minds Biosciences beats Trevi Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Bright Minds Biosciences (NASDAQ:DRUG) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MBX Biosciences has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, suggesting that its stock price is 634% less volatile than the broader market.

MBX Biosciences presently has a consensus price target of $60.22, suggesting a potential upside of 4.19%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 112.77%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Bright Minds Biosciences' return on equity of -20.58% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, MBX Biosciences had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Bright Minds Biosciences. MBX Biosciences' average media sentiment score of 0.00 equaled Bright Minds Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Summary

MBX Biosciences beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Bright Minds Biosciences has a beta of -5.34, indicating that its share price is 634% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Bright Minds Biosciences' return on equity of -20.58% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

In the previous week, Nurix Therapeutics had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Nurix Therapeutics and 1 mentions for Bright Minds Biosciences. Nurix Therapeutics' average media sentiment score of 0.41 beat Bright Minds Biosciences' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bright Minds Biosciences has higher earnings, but lower revenue than Nurix Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Nurix Therapeutics	$83.98M	29.53	-$264.46M	-$3.16	N/A

40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bright Minds Biosciences currently has a consensus price target of $143.83, suggesting a potential upside of 112.77%. Nurix Therapeutics has a consensus price target of $32.20, suggesting a potential upside of 34.28%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Bright Minds Biosciences is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Bright Minds Biosciences beats Nurix Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Kodiak Sciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Bright Minds Biosciences has a beta of -5.34, suggesting that its share price is 634% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 0.00 equaled Kodiak Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Kodiak Sciences	N/A	-253.85%	-81.48%

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 112.77%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 9.35%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Bright Minds Biosciences beats Kodiak Sciences on 6 of the 10 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$657.90M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-27.70	21.61	28.02	24.70
Price / Sales	N/A	325.99	534.82	99.69
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	8.12	8.66	10.96	6.46
Net Income	-$8.74M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.75%	3.39%	2.12%	1.69%
1 Month Performance	-2.03%	10.81%	5.25%	3.81%
1 Year Performance	138.87%	62.61%	33.29%	23.90%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	2.1522 of 5 stars	$67.60 flat	$143.83 +112.8%	+138.9%	$657.90M	N/A	N/A	N/A	News Coverage Analyst Upgrade
TARS Tarsus Pharmaceuticals	2.9203 of 5 stars	$62.93 +2.7%	$90.67 +44.1%	+59.3%	$2.71B	$535.08M	N/A	50	News Coverage
TRVI Trevi Therapeutics	2.1929 of 5 stars	$18.67 +0.2%	$22.90 +22.7%	+204.1%	$2.65B	N/A	N/A	20
MBX MBX Biosciences	0.8211 of 5 stars	$55.16 +2.4%	$60.22 +9.2%	N/A	$2.63B	N/A	N/A	N/A	News Coverage Gap Down
NRIX Nurix Therapeutics	3.1925 of 5 stars	$24.26 +1.7%	$32.20 +32.7%	+88.4%	$2.51B	$83.98M	N/A	300	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. TARS, TRVI, MBX, NRIX, and KOD

How does Bright Minds Biosciences compare to Tarsus Pharmaceuticals?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Summary

How does Bright Minds Biosciences compare to MBX Biosciences?

Summary

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. TARS, TRVI, MBX, NRIX, and KOD

How does Bright Minds Biosciences compare to Tarsus Pharmaceuticals?

Do insiders & institutionals have more ownership in TARS or DRUG?

Which has stronger earnings & valuation, TARS or DRUG?

Do analysts prefer TARS or DRUG?

Is TARS or DRUG more profitable?

Does the media refer more to TARS or DRUG?

Which has more volatility & risk, TARS or DRUG?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Is TRVI or DRUG more profitable?

Does the media refer more to TRVI or DRUG?

Do analysts prefer TRVI or DRUG?

Which has better earnings and valuation, TRVI or DRUG?

Do institutionals and insiders have more ownership in TRVI or DRUG?

Which has more volatility and risk, TRVI or DRUG?

Summary

How does Bright Minds Biosciences compare to MBX Biosciences?

Do institutionals & insiders have more ownership in MBX or DRUG?

Which has more risk & volatility, MBX or DRUG?

Do analysts prefer MBX or DRUG?

Is MBX or DRUG more profitable?

Does the media prefer MBX or DRUG?

Which has higher valuation and earnings, MBX or DRUG?

Summary

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Which has more volatility & risk, DRUG or NRIX?

Is DRUG or NRIX more profitable?

Does the media favor DRUG or NRIX?

Which has better valuation & earnings, DRUG or NRIX?

Do insiders & institutionals hold more shares of DRUG or NRIX?

Do analysts prefer DRUG or NRIX?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Which has more risk & volatility, DRUG or KOD?

Does the media prefer DRUG or KOD?

Is DRUG or KOD more profitable?

Do institutionals & insiders have more ownership in DRUG or KOD?

Which has higher earnings and valuation, DRUG or KOD?

Do analysts prefer DRUG or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools